Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The slope of the estimated glomerular filtration rate (eGFR) has recently gained attention as a surrogate endpoint for end-stage kidney disease (ESKD). In Japan, regulatory guidelines for developing treatments targeting early chronic kidney disease (CKD) also recognize the potential of the eGFR slope as a surrogate endpoint. However, much of the existing evidence is based on large cohort studies using health screening data or clinical trial participants. Evidence regarding the association between the eGFR slope and subsequent clinical outcomes in patients managed under routine nephrology care remains limited. This study aimed to investigate the relationship between the 2-year eGFR slope and the subsequent 12-year incidence of ESKD, cardiovascular events, and all-cause mortality in CKD patients receiving nephrologist-led care.
This prospective observational study included 500 CKD patients receiving care from nephrologists at five medical institutions in Nagano Prefecture. Patients with at least six eGFR measurements over a 2-year period were analyzed. The eGFR slope was calculated using the least squares method. Outcomes assessed during the 12-year follow-up were kidney failure requiring dialysis (renal death), all-cause mortality, and cardiovascular events. The associations between the eGFR slope and each outcome were examined using multivariable Cox proportional hazards models, adjusting for relevant confounders.
Of the 500 patients, 334 met the inclusion criteria for analysis. The mean age was 65.2 years (SD 12.9), and 67.9% were male. Diabetes was present in 12.5%, and hypertension in 54.2%. The median baseline eGFR was 35.3 mL/min/1.73 m² (interquartile range: 22.9–45.9). The mean eGFR slope was −0.8 ± 3.0 mL/min/1.73 m²/year. During the 12-year follow-up, 120 patients (35.9%) progressed to dialysis, 101 (30.2%) died, and 70 (21.0%) experienced cardiovascular events. Each 1.0 mL/min/1.73 m²/year slower decline in eGFR was significantly associated with a reduced risk of ESKD (hazard ratio [HR]: 0.74, 95% confidence interval [CI]: 0.69–0.76). No significant associations were observed between the eGFR slope and all-cause mortality (HR: 0.98, 95% CI: 0.90–1.06) or cardiovascular events (HR: 0.97, 95% CI: 0.89–1.06).
Consistent with prior evidence linking the eGFR slope to ESKD risk, this study confirms that, in routine nephrology care settings with long-term follow-up, the eGFR slope is a robust surrogate marker for kidney outcomes. These findings support the utility of the eGFR slope as a clinically valuable indicator for managing and evaluating treatment in CKD patients.
